Clinical Trials
Below are current clinical trials.
272 studies in Infectious Diseases Research (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Jacksonville, Fla.
The purpose of this study is to evaluate the safety and tolerability of PC945 for the prevention of fungal aspergillus infections in the lung in patients who have received a lung transplant.
-
Rochester, Minn.
The study will involve administering the study drug as a single dose of study drug or placebo. This study is designed to demonstrate the superiority of the experimental drug versus placebo in adult patients with recurrent CDI.
-
Rochester, Minn.
We purpose of this study is to evaluate the diagnosis accuracy of the Controlled Attenuation Parameter (CAP) measured by FibroScan® (both with M and XL probes) in all patients who are undergoing liver biopsy for any liver disease.
-
Rochester, Minn.
The purpose of this study is to assess patients suspected of recurrent C. difficile disease (rCDI) and using a combination of clinical and laboratory markers to determine disease versus post infectious irritable bowel syndrome (IBS) with C. difficile colonization.
-
Rochester, Minn.
The purpose of this study is to explore lay understandings toward participating in and perceptions of consent to biospecimen research and valuation of genetics in SARS-COV-2 infection, testing, immunity, and vaccine development, to explore professional attitudes toward and perception of barriers and facilitators for implementating genetic technology to facilitate understanding of SARS-COV-2 infection and immunity, improvement and scale-up of testing, and vaccine development, and to identify ethical, social, and inter-professional aspects of microbial genetic technology implementation in population health surveillance, clinical test development, and vaccine research.We hypothesize that engagement with individuals whom directly experience and/or are impacted by the increasing use of SARS-Cov-2 genetic technology, including COVID-19 Pandemic Response Biobank contributors and interdisciplinary expert teams will help identify ethical and social issues in adopting and implementing emerging technology.
-
Scottsdale/Phoenix, Ariz.
The purpose of this study is to compare the safety and effectiveness of using ABT-493/ABT-530, to the combination of sofosbuvir and daclatasvir in treating adults with genotype 3 chronic hepatitis C virus infection.
-
Scottsdale/Phoenix, Ariz.
This is a Multicenter, Double-Blind, Parallel-Arm, Placebo-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Oral Full-Spectrum Microbiota® (CP101) in Subjects with Recurrence of Clostridium difficile Infection (PRISM3)
-
Rochester, Minn.
The purpose of this study is to evaluate the effectiveness, safety and tolerability of Oral Full-Spectrum MicrobiotaTM (CP101) in subjects with recurrence of Clostridium difficile infection.
-
Rochester, Minn.
The purpose of this study is to:
-
To determine the prevalence of MBL in patients with chronic hepatitis C who are to begin therapy with DAA, and compare with clinic controls who are seen in the general medicine clinic at Mayo Clinic
-
To determine the correlation between the specific subtype of MBL (CD5- MBL, atypical CLL-phenotype MBL and CLL-phenotype MBL) relative to the HCV genotype
-
To assess the proportion of individuals with MBL who have an improvement in the circulating monoclonal B-cell population following therapy with DAA
-
Rochester, Minn., Scottsdale/Phoenix, Ariz.
A Phase 3b, single arm, open-label, multicenter study to evaluate the safety and to demonstrate the non-inferiority of the sustained virologic response 12 weeks post dosing (SVR12) rates of 8 weeks of treatment with the glecaprevir (GLE)/pibrentasvir (PIB) combination regimen to the historical SVR12 rate of 12 weeks of treatment with the GLE/PIB in treatment-naïve adults with chronic HCV GT 1, 2, 4, 5, or 6 infection and compensated cirrhosis.